Ticker
AGEN

Price
2.89
Stock movement down
-0.10 (-3.34%)
Company name
Agenus Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsverdi
817.46M
Ent verdi
983.41M
Pris/omsetning
2.64
Pris/bok
52.01
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
-52.47%
3 års avkastning
0.82%
5 års avkastning
-4.25%
10 års avkastning
-4.64%
Sist oppdatert: 2022-08-25

UTBYTTE

AGEN betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF1641.49
Pris til FCF-
Pris til EBITDA12.58
EV i forhold til EBITDA15.13

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning2.64
Pris til bok52.01
EV i forhold til salg3.17

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall282.86M
EPS (TTM)-0.09
FCF per aksje (TTM)-0.22

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)309.89M
Bruttofortjeneste (TTM)69.78M
Driftsinntekter (TTM)67.17M
Netto inntekt (TTM)-23.43M
EPS (TTM)-0.09
EPS (1 år fremover)-0.64

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)22.52%
Driftsmargin (TTM)21.68%
Fortjenestemargin (TTM)-7.56%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter247.71M
Netto fordringer1.29M
Samlede omløpsmidler290.48M
Goodwill24.62M
Immaterielle eiendeler7.75M
Eiendom, anlegg og utstyr0.00
Sum eiendeler441.31M
Leverandørgjeld34.54M
Kortsiktig/nåværende langsiktig gjeld64.31M
Sum kortsiktig gjeld163.06M
Sum gjeld413.65M
Aksjonærenes egenkapital15.72M
Netto varige driftsmidler231.36M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)498.00K
Kapitalutgifter (TTM)55.16M
Fri kontantstrøm (TTM)-54.67M
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-149.03%
Avkastning på eiendeler-5.31%
Avkastning på investert kapital-149.03%
Kontantavkastning på investert kapital-347.79%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning3.03
Daglig høy3.04
Daglig lav2.87
Daglig volum2.37M
Tidenes høyeste315.75
1 år analytikerestimat9.67
Beta1.08
EPS (TTM)-0.09
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon7 Nov 2022

Nedsidepotensial

Loading...
Nedsidepotensial-data
AGENS&P500
Nåværende prisfall fra toppnotering-99.08%-12.18%
Høyeste prisfall-99.59%-56.47%
Dato for høyeste fall14 Jun 20229 Mar 2009
Gj.snittlig fall fra topp-92.62%-11.38%
Gj.snittlig tid til ny topp1892 days12 days
Maks tid til ny topp5653 days1805 days
SELSKAPSOPPLYSNINGER
AGEN (Agenus Inc) company logo
Markedsverdi
817.46M
Markedsverdi kategori
Small-cap
Beskrivelse
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Ansatte
441
SEC-innsendelser
Adm. direktør
Garo H. Armen
Land
USA
By
Lexington
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
Merck (MRK) gets a favorable ruling from a district court of West Virginia in two patents related to Januvia/Janumet against Viatris, which is looking to market its generic versions of the medicines i...
23. september 2022
In the latest trading session, Agenus (AGEN) closed at $2.31, marking a -1.28% move from the previous day.
19. september 2022
Agenus (AGEN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
19. september 2022
J&J (JNJ) to buy back $5 billion worth of shares. It also reaffirms its financial guidance for 2022.
15. september 2022
Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.
14. september 2022
FDA accepts Pfizer's (PFE) NDA for ritlecitinib for treating severe alopecia areata. The EMA also accepts the MAA for a similar patient population.
12. september 2022
Phase 2 ACTIVATE trials to advance globally in metastatic patients who have progressed on available therapiesBotensilimab, alone and in combination with balstilimab (PD-1), has demonstrated robust cli...
12. september 2022
Patricia Carlos named Chief Regulatory, Quality, and Safety OfficerTodd Yancey, MD named Senior Global Clinical Development, Medical Affairs and Commercial Advisor LEXINGTON, Mass., Sept. 12, 2022 (GL...
12. september 2022
Pfizer (PFE) gets Breakthrough Therapy Designation for GBS vaccine candidate, GBS6, based on an interim analysis of a phase II study.
8. september 2022
GSK's regulatory applications for daprodustat are based on data from the ASCEND phase III program, consisting of five studies.
7. september 2022
Neste side